

H 2
-- Claim 13 (new). The method according to claim 3 wherein the overproduction of NPY is caused by a polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of the human preproNPY. --

-- Claim 14 (new). The method according to claim 4 wherein the overproduction of NPY is caused by a polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of the human preproNPY. --


-- Claim 15 (new). The method according to claim 5 wherein the overproduction of NPY is caused by a polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of the human preproNPY. --

-- Claim 16 (new). The method according to claim 6 wherein the overproduction of NPY is caused by a polymorphism comprising the substitution of the position 7 leucine for proline in the signal peptide part of the human preproNPY. --

REMARKS

The specification has been amended to indicate the presence of a color drawings. The claims have been amended to remove multiple dependencies and to bring them more in line with U.S. practice. It is believed that these amendments do not constitute new matter and their entry is requested.

Respectfully submitted,



Jeffrey L. Ihnen
Registration No. 28,957
Attorney for Applicants
ROTHWELL, FIGG, ERNST & MANBECK, P.C.
555 Thirteenth Street, N.W., Suite 701-E
Washington, D.C. 20004
(202) 783-6040

Dated: 25 August 2000
2630\...106A PAM